← Back to Search

Virus Therapy

AIV001 for Basal Cell Carcinoma

Phase 1 & 2
Waitlist Available
Research Sponsored by AiViva BioPharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 119 days
Awards & highlights

Study Summary

This trial is testing a new treatment for a low-risk type of skin cancer.

Eligible Conditions
  • Basal Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 119 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 119 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse events
Secondary outcome measures
Clearance of basal cell carcinoma

Trial Design

4Treatment groups
Experimental Treatment
Group I: AIV001 Treatment Dose 4Experimental Treatment1 Intervention
Intradermal/intratumoral, Dose 4
Group II: AIV001 Treatment Dose 3Experimental Treatment1 Intervention
Intradermal/intratumoral, Dose 3
Group III: AIV001 Treatment Dose 2Experimental Treatment1 Intervention
Intradermal/intratumoral, Dose 2
Group IV: AIV001 Treatment Dose 1Experimental Treatment1 Intervention
Intradermal/intratumoral, Dose 1
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AIV001
2018
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

AiViva BioPharma, Inc.Lead Sponsor
5 Previous Clinical Trials
74 Total Patients Enrolled
~5 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top